Assessment of Toxicity After 68Ga-PSMA-PET-Imaging Based Treatment Planning and Dose-Escalation in Radiation Therapy in Prostate Cancer Patients

PURPOSE: Effective tumor control in prostate cancer demands elevated radiation doses given its low alpha/beta ratio. We investigated in primary and recurrent prostate cancer whether dose-escalated-radiation therapy (DE-RT) based on 68Ga-PSMA-PET positive lesions yields increased toxicity. METHODS: We evaluated 90 patients (salvage DE-RT: 67 patients, DE-re-RT: 11 patients, definite DE-RT: 12 patients) who were treated based on a pre-treatment hybrid 68Ga-PSMA. Findings from pre-treatment hybrid 68Ga-PSMA-PET could result in an adaption of radiation planning. Common Toxicity Criteria of Adverse Effects (Version 4.03) were used to assess toxicity, this was done before the initiation and at the end of DE-RT, as well as at the first and last follow-up (F/U) examination. We evaluated the change in toxicity for each interval for the collective as well as in a per-patient analysis.RESULTS: Findings in 68Ga-PSMA-PET-imaging resulted in a change of TNM-stage in 61.1% and an adapted treatment concept in 71.1% of patients. When comparing overall toxicity before DE-RT and at the last follow-up, 5.9% treatment-related side effects (grade 1-3) occurred with 1.7% of them being severe (grade 3). In a patient-centered approach we examined the intra-individual changes in toxicity before and after DE-RT. At the last F/U, the majority out of 80 patients (range: 61.3-93.8%) stated unchanged toxicity rates compared to the toxicity examined at the initiation of RT.CONCLUSION: The rate of treatment-related toxicity (grade 1-2) due to DE-RT in our cohort is 4.2%. For grade 3 toxicity it is 1.7%, respectively. The overall level of toxicity is highest during and shortly after completion of DE-RT (+7.4%) and improves over time until the last reported F/U (+5.9%). Compared to historical data, the toxicity profile of DE-RT is not increased. Therefore it is possible to apply DE-RT with the aim to increase tumor control by precisely treating all involved areas according to PSMA-PET-imaging.

[1]  J. Westhuyzen,et al.  PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Roger Slavik,et al.  18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. , 2019, The Lancet. Oncology.

[3]  J. Debus,et al.  Elective Node Irradiation With Integrated Boost to the Prostate Using Helical IMRT–Clinical Outcome of the Prospective PLATIN-1 Trial , 2019, Front. Oncol..

[4]  J. Smith-Palmer,et al.  Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada , 2019, BMC Urology.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  C. Stief,et al.  Outcome After PSMA PET/CT–Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis , 2018, The Journal of Nuclear Medicine.

[7]  D. Bailey,et al.  A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol , 2018, BJU international.

[8]  C. Stief,et al.  Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy , 2018, Radiation Oncology.

[9]  I. Vogelius,et al.  Dose Response and Fractionation Sensitivity of Prostate Cancer After External Beam Radiation Therapy: A Meta-analysis of Randomized Trials. , 2017, International journal of radiation oncology, biology, physics.

[10]  P. Wust,et al.  Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients , 2017, Radiation oncology.

[11]  K. Schiller,et al.  Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after 68Ga-PSMA-PET imaging , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  S. Combs,et al.  68Ga‐PSMA‐PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment , 2017, The Prostate.

[13]  G. Sanguineti,et al.  Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Dearnaley,et al.  Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial , 2016, The Lancet. Oncology.

[15]  B. Heijmen,et al.  Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[16]  Markus Schwaiger,et al.  Current use of PSMA–PET in prostate cancer management , 2016, Nature Reviews Urology.

[17]  S. Combs,et al.  Protons, Photons, and the Prostate – Is There Emerging Evidence in the Ongoing Discussion on Particle Therapy for the Treatment of Prostate Cancer? , 2016, Front. Oncol..

[18]  B. Heijmen,et al.  Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. , 2015, The Lancet. Oncology.

[19]  S. Ziegler,et al.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  B. Hickey,et al.  Adjuvant radiotherapy following radical prostatectomy for prostate cancer. , 2011, The Cochrane database of systematic reviews.

[21]  A. D'Amico.  Risk-based management of prostate cancer. , 2011, The New England journal of medicine.

[22]  Yoshiya Yamada,et al.  Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. , 2008, International journal of radiation oncology, biology, physics.

[23]  Michael J. Zelefsky,et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.

[24]  C C Ling,et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. , 2001, The Journal of urology.

[25]  M. Schwaiger,et al.  Integration of 68 Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study , 2016 .

[26]  B. Heijmen,et al.  Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial. , 2015, The Lancet. Oncology.

[27]  P. Carroll,et al.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.